Printer Friendly

Medical Diagnostic Laboratories offers new prenatal Cystic Fibrosis tests.

M2 PHARMA-October 22, 2014-Medical Diagnostic Laboratories offers new prenatal Cystic Fibrosis tests

(C)2014 M2 COMMUNICATIONS

22 October 2014 - US CLIA-certified, CAP-accredited lab Medical Diagnostic Laboratories LLC, or MDL, said Wednesday it had started offering new prenatal Cystic Fibrosis (CF) tests which use next-generation DNA sequencing platforms.

Particularly, the lab offers non-invasive, easy specimen collection methods for CF testing using mouthwash samples, cervico-vaginal swabs or blood. Using next-generation DNA sequencing platforms, MDL offers a comprehensive panel for CF testing, which delivers high accuracy genetic data.

The assays include the MDL Cystic Fibrosis Core Test, a cystic fibrosis transmembrane conductance regulator (CFTR) gene sequence analysis that screens for the 23 major mutations recommended by the American College of Medical Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG) for CF screening.

The lab also offers the MDL Cystic Fibrosis Comprehensive Test, an expanded CFTR gene sequence analysis that screens for 191 variants, including the recommended 23 major mutations, in addition to nine mutations recommended by the US FDA to determine treatment efficacy of Kalydeco (ivacaftor).

Finally, the MDL Cystic Fibrosis Site Specific Analysis screens for known family CF mutations priorly detected in blood relatives.

MDL is a member of New Jersey-based Genesis Biotechnology Group.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 22, 2014
Words:216
Previous Article:Agilent introduces updated miRNA Microarrays featuring targets from latest miRBase database.
Next Article:Oramed Pharmaceuticals announces positive top-line clinical results from Phase IIa clinical trial of ORMD-0801 for treatment of type 1 diabetes.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters